Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velora Pioneer: HMB-002 in Von Willebrand Disease
NCT06754852Phase 2Recruiting
- Sponsor
- Hemab Therapeutics
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of HMB-002 in von Willebrand disease (VWD), sponsored by Hemab Therapeutics. Started Feb 2025; status: recruiting.
02
Drugs
HMB-002
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT06754852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754852.